NFKB1 and severe acute respiratory syndrome: Most importantly, treatment with these drugs that inhibited NF-κB activation led to reduction in inflammation and lung pathology in both SARS-CoV-infected cultured cells and mice and significantly increased mouse survival after SARS-CoV infection.